Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYun Kyoung TigerRARoshan AsraniANAdrienne Nedved

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study shows Glofit-GemOx yields 78% overall response rate in relapsed/refractory aggressive B-cell lymphoma, indicating potential as effective therapy.

Key Points

  • To evaluate the real-world efficacy of Glofit plus GemOx in patients with relapsed/refractory aggressive B-cell lymphoma.
  • Conducted a multicenter retrospective study across 8 U.S. academic centers.
  • Identified 31 patients with relapsed/refractory aggressive B-cell lymphoma treated with Glofit-GemOx.
  • Abstracted data on baseline characteristics, treatment history, and outcomes from medical records.
  • Overall response rate (ORR) was 78% in evaluable patients.
  • Complete response (CR) rate was 41% among all evaluable cases.
  • Majority of patients had advanced stage disease, with 90% presenting with stage III/IV.

Cite This Study

Tiger et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5aahttps://doi.org/10.1182/blood-2025-1956
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups2025 · 3 citations
  2. 2Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  5. 5Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO2026